title: Effects of flunixin meglumine on pyrexia and bioenergetic variables in postparturient dairy cows.
abstract: Study objectives were to determine whether a nonsteroidal antiinflammatory drug would reduce parturition-induced inflammation and fever and consequently improve appetite, bioenergetic parameters, and production variables in transitioning dairy cows. Multiparous cows (n = 26) were randomly assigned to 1 of 2 treatments beginning at parturition: 1) flunixin meglumine (FM; 2.2 mg/kg of BW; Banamine, 50 mg/mL, Schering-Plough Animal Health, Kenilworth, NJ), or 2) saline (control) at 2.0 mL/45.5 kg of BW. All treatments were administrated i.v. daily for the first 3 d in milk (DIM). Individual milk yield and dry matter intake (DMI) were recorded daily for the first 35 DIM. Rectal temperature was measured daily at 0700 and 1600 h for the first 7 DIM. Milk composition was determined on 2, 7, 14, 21, 28, and 35 DIM and blood plasma was collected on 1, 2, 3, 4, 7, 14, 21, 28, and 35 DIM. Body weight and body condition score were determined on -7, 1, 7, 14, 21, 28, and 35 DIM. Flunixin meglumine treatment slightly increased rectal temperature (38.99 vs. 38.76 degrees C) during the first 7 DIM and reduced overall DMI (22.04 vs. 19.48 kg/d), but there were no treatment differences in overall milk yield (35.2 kg/d), 3.5% fat-corrected milk (37.6 kg/d), energy-corrected milk (37.7 kg/d), DMI (2.97% of BW), or overall energy balance (-2.32 Mcal/d). There were no treatment differences in milk fat (3.91%), protein (3.32%), or lactose (4.57%). Treatment had no effect on plasma glucose (66.5 mg/dL) or nonesterified fatty acids (553 microEq/L), but plasma urea nitrogen tended to be less in FM-treated cows (16.4 vs. 14.5 mg/dL). Daily FM administration to cows for the first 3 d after parturition slightly increased rectal temperatures by 0.23 degrees C, reduced feed intake, and did not improve production or energetic variables during the first 35 DIM in transition dairy cows.
authors.affiliation: Department of Animal Sciences, The University of Arizona, Tucson 85721, USA.
authors.forename: G
authors.initials: G
authors.lastname: Shwartz
authors.forename: K L
authors.initials: KL
authors.lastname: Hill
authors.forename: M J
authors.initials: MJ
authors.lastname: VanBaale
authors.forename: L H
authors.initials: LH
authors.lastname: Baumgard
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D001806:Blood Urea Nitrogen; D001831:Body Temperature / Q000187:drug effects; D002417:Cattle; D002418:Cattle Diseases / Q000188:drug therapy*; D003002:Clonixin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D003612:Dairying; D004435:Eating / Q000187:drug effects; D004734:Energy Metabolism / Q000187:drug effects / Q000502:physiology*; D005260:Female; D005334:Fever / Q000188:drug therapy / Q000662:veterinary*; D007774:Lactation / Q000187:drug effects; D008892:Milk / Q000737:chemistry / Q000378:metabolism; D049590:Postpartum Period; D011448:Prostaglandin Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D011897:Random Allocation
chemical_list: D001786:Blood Glucose; D011448:Prostaglandin Antagonists; C014558:flunixin meglumine; D003002:Clonixin